Inhibrx Biosciences, Inc. (INBX) stock forecast and price target
Price $83.30 · data as of November 13, 2026
12-month price target
Average target$266.67
Upside / downside+220.1%
Analysts3
ConsensusStrong buy
Low $230.00Average $266.67High $325.00
Gold marker: average target · white marker: today’s price ($83.30)
Analyst ratings
Strong buy 0Buy 3Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-9.26 | −2.4% | $0 |
| Next fiscal year ends December 31, 2027 | $-8.76 | +5.3% | $32M |
| Next quarter ends December 31, 2026 | $-2.42 | −14.4% | $0 |
| Quarter after ends March 31, 2027 | $-2.37 | −10.2% | $1M |
Consensus of the analysts covering Inhibrx Biosciences, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Frequently asked questions
What is the Inhibrx Biosciences stock price target?
The average 12-month target from 3 analysts is $266.67, 220.1% above the current price of $83.30 Targets range from $230.00 to $325.00.
Is Inhibrx Biosciences a buy according to analysts?
The consensus rating is “Strong buy” (3 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Inhibrx Biosciences expected to earn?
Analysts expect EPS of $-9.26 for the fiscal year ending December 31, 2026 and $-8.76 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.